Inactive Instrument

Medivation Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

28/10/16	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
07/09/16	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE

28/10/16	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
07/09/16	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE
08/07/16	Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	RE
04/06/16	Medivation : Ex-Oppenheimer adviser arrested for trading on Pfizer employee's tips	RE
02/06/16	Medivation : sets eligibility date for shareholder consent on board revamp	RE
25/05/16	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
25/05/16	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
25/05/16	Exclusive: Sanofi to unveil challenge to Medivation's board - sources	RE
10/05/16	Astellas Pharma : Medivation succumbs to pressure to explore sale - sources	RE
09/05/16	Exclusive - Medivation succumbs to pressure to explore sale: sources	RE
06/05/16	Medivation : Sanofi ready to up offer for drugmaker Medivation, could oust board	RE
04/05/16	Medivation : Sanofi sees 'strong strategic' fit with U.S. Medivation	RE
04/05/16	Exclusive: Pfizer approaches Medivation about potential takeover - sources	RE

09/10/16	Medivation : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo	BU
09/09/16	Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit Against Medivation, Inc.	PR
26/08/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
25/08/16	Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders	BU
24/08/16	SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. -MDVN	PR

28/10/16	Sanofi : relève ses prévisions pour 2016 et s'envole en Bourse
28/10/16	Sanofi : relève ses prévisions pour 2016 et veut céder ses activités génériques en Europe
10/10/16	Medivation : Neue, im Rahmen der ESMO 2016 präsentierte Ergebnisse belegen zusätzlich, dass XTANDITM▼ (Enzalutamid) die Zeit bis zur PSA-Progression bei fortgeschrittenem Prostatakarzinom im Vergleich zu Placebo signifikant verlängert
10/10/16	Medivation : De nouvelles données présentées au Congrès 2016 de l’ESMO démontrent une fois de plus que XTANDITM▼ (enzalutamide) améliore nettement, par rapport au placebo, le délai avant progression du PSA en cas de cancer de la prostate avancé
19/09/16	Sanofi : poursuit Merck en justice aux USA pour protéger les brevets de Lantus

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.25%	-1.36%	+44.08%	+102.76%	68.24B
ARGENX SE	+1.08%	-3.18%	+32.13%	+75.96%	62.23B
INSMED INCORPORATED	-1.18%	+0.47%	-12.78%	+384.69%	27.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.86B
BIONTECH SE	-1.76%	-6.30%	-4.55%	-19.75%	24.22B
GENMAB A/S	+0.19%	-3.42%	+14.80%	-19.33%	19.36B
PHARMAESSENTIA CORPORATION	-1.86%	-2.22%	+202.03%	+353.89%	17.28B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.46B
EXELIXIS, INC.	-1.54%	-2.88%	+52.33%	+159.75%	14.23B
Average	-0.92%	-3.30%	+39.26%	+171.52%	30.3B
Weighted average by Cap.	-0.47%	-3.10%	+35.75%	+137.11%